Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
R&D Systems™ Recombinant Rat Lymphotoxin beta R/TNFRSF3 Fc Chimera
Click to view available options
Quantity:
50 μg
Description
The Recombinant Rat Lymphotoxin beta R/TNFRSF3 Fc Chimera is derived from NS0. The Recombinant Rat Lymphotoxin beta R/TNFRSF3 Fc Chimera has been validated for the following applications: Bioactivity.
Specifications
Specifications
For Use With (Application) | Bioactivity |
Gene ID (Entrez) | 4055 |
Molecular Weight (g/mol) | Observed M.W.: 60-68kDa, reducing conditions, Theoretical M.W.: 49kDa |
Quantity | 50 μg |
Source | Mouse myeloma cell line,NS0-derived rat Lymphotoxin beta R/TNFRSF3 protein, (N-terminus) Rat Lymphotoxin beta R (Gln29-Met222) Accession &Num; NP_001008316 IEGRMDP Mouse IgG2a (Glu98-Lys330) (C-terminus) |
Storage Requirements | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution. |
Endotoxin Concentration | <0.10 EU per 1μg of the protein by the LAL method. |
Gene Alias | CD18, D12S370, ltbetar, LT-BETA-R, LTBR, lymphotoxin B receptor, lymphotoxin beta receptor (TNFR superfamily, member 3), Lymphotoxin-beta receptor, LymphotoxinbR, TNF RIII, TNF Rrp, TNFCRTNF-RIII, TNFR superfamily, member 3, TNFR2-RP, TNFR3, TNF-R-III, TNFR-RP, TNFRSF3, TNFRSF3TNFR-III, Tumor necrosis factor C receptor, Tumor necrosis factor receptor 2-related protein, tumor necrosis factor receptor superfamily member 3, tumor necrosis factor receptor superfamily, member 3, Tumor necrosis factor receptor type III |
Common Name | Lymphotoxin beta R/TNFRSF3 |
Gene Symbol | Ltbr |
Show More |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction